This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Parkinson's disease (PD)	Leucine-rich repeat kinase 2 (LRRK2)	<p>Studies in mice and in cell culture identified a selective LRRK2 inhibitor that could help treat PD. <i>In vitro</i>, the small molecule LRRK2-IN-1 had IC₅₀ values of 13 and 6 nM against wild-type LRRK2 and a mutant LRRK2 found in PD patients, respectively. Next steps could include evaluating LRRK2-IN-1 in animal models of PD.</p> <p>H. Lundbeck A/S has partnerships with two biotech companies—Zenobia Therapeutics Inc. and Vernalis Group plc—for LRRK2 inhibitors that are in preclinical development.</p> <p>TauTaTis Inc.'s TTT-3002, an LRRK2 inhibitor, is in preclinical development for PD.</p> <p>SciBX 4(12); doi:10.1038/scibx.2011.347 Published online March 24, 2011</p>	Patent and licensing status unavailable	<p>Deng, X. <i>et al. Nat. Chem. Biol.</i>; published online March 6, 2011; doi:10.1038/nchembio.538</p> <p>Contact: Nathanael S. Gray, Dana-Farber Cancer Institute, Boston, Mass. e-mail: nathanael_gray@dfci.harvard.edu</p> <p>Contact: Dario R. Alessi, University of Dundee, Dundee, U.K. e-mail: d.r.alessi@dundee.ac.uk</p>